ImmunityBio, Inc., a vertically-integrated commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include cytokine fusion proteins, vaccine vectors, and cell therapies. The company's platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. The company is based in San Diego, California.

ImmunityBio Inc.

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on ImmunityBio, with a price target of $15.00. Y. Mald...

Market Cap	$8.13B	P/E Ratio	N/A
52W High	$12.43	52W Low	$1.95
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	28.5%	52W Position	55.6%
Overall Score	43	Value Score	40
Quality Score	39	Technical Score	50

EPS Current Est	$-0.31	EPS Next Est	$-0.14
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IBRX	$7.78	+7.76%	15.68M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IBRX	$7.78	+7.8%	15.68M
3
4
5
6

IBRX

IBRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ImmunityBio Inc. Data in Excel

Get ImmunityBio Inc. Data in Excel